Category: News

Today, the Luxembourgish newspaper “Luxemburger Wort” published a long article describing the attempts of OrganoTherapeutics to use human midbrian organoids (mini-brains) to develop new therapies against Parkinson’s disease. The article can be found here: https://www.wort.lu/de/business/start-up-organotherapeutics-gehirn-aus-der-petrischale-5e297596da2cc1784e354964

We are very happy to announce that our project “Analysis of Parkinson’s disease associated alpha-Synuclein aggregate toxicity in patient specific brain organoids” has been selected for funding via the Alan and Helene Goldberg grant (CAAT grant). This is a great achievement for OrganoTherapeutics and we are looking forward to start […]

OrganoTherapeutics and the University of Luxembourg / LuxembourgCentre for Systems Biomedicine signed a joint Memorandum of Understanding. This MOU particularly concerns the future relationship in the field of drug development projects.

This new manuscript describes the usage of our midbrain organoid for Neuro-Toxicology applications. A major challenge in the field of neurodegenerative diseases is the poor translation of pre-clinical models to clinical applications. The human brain is an immensely complex structure, which makes it difficult to recapitulate its development, function and […]

On the platform INDIEGOGO we have started a new Crowdfunding Campaign with the title “Medication development free of animal testing”. With this campaign we want to select funding to further advance two drug candidates against Parkinson’s disease in animal testing free approaches. Please find the campaign here: https://www.indiegogo.com/projects/medication-development-free-of-animal-testing?utm_medium=email&utm_source=lifecycle&utm_campaign=#/ Update 20.01.20120: […]

OrganoTherapeutics and Neurolixis are happy to announce the conclusion of a collaboration agreement.